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Background: The randomized, double-blind Multiple Out-
comes of Raloxifene Evaluation (MORE) trial found that 4
years of raloxifene therapy decreased the incidence of invasive
breast cancer among postmenopausal women with osteoporosis
by 72% compared with placebo. We conducted the Continuing
Outcomes Relevant to Evista (CORE) trial to examine the
effect of 4 additional years of raloxifene therapy on the inci-
dence of invasive breast cancer in women in MORE who
agreed to continue in CORE. Methods: Women who had been
randomly assigned to receive raloxifene (either 60 or 120 mg/
day) in MORE were assigned to receive raloxifene (60 mg/day)
in CORE (n  3510), and women who had been assigned to
receive placebo in MORE continued on placebo in CORE (n
1703). Breast cancer incidence was analyzed by a log-rank
test, and a Cox proportional hazards model was used to
compute hazard ratios (HRs) and 95% confidence inter-
vals (CIs). All statistical tests were two-sided. Results:
During the CORE trial, the 4-year incidences of invasive
breast cancer and estrogen receptor (ER)-positive inva-
sive breast cancer were reduced by 59% (HR  0.41; 95%
CI  0.24 to 0.71) and 66% (HR  0.34; 95% CI  0.18
to 0.66), respectively, in the raloxifene group compared
with the placebo group. There was no difference between
the two groups in incidence of ER-negative invasive breast
cancer during CORE (P  .86). Over the 8 years of both
trials, the incidences of invasive breast cancer and ER-
positive invasive breast cancer were reduced by 66% (HR
 0.34; 95% CI  0.22 to 0.50) and 76% (HR  0.24; 95%
CI  0.15 to 0.40), respectively, in the raloxifene group
compared with the placebo group. During the CORE trial,
the relative risk of thromboembolism in the raloxifene
group compared with that in the placebo group was 2.17
(95% CI  0.83 to 5.70). This increased risk, also ob-
served in the MORE trial, persisted over the 8 years of
both trials. Conclusions: The reduction in invasive breast
cancer incidence continues beyond 4 years of raloxifene treat-
ment in postmenopausal women with osteoporosis. No new
safety concerns related to raloxifene therapy were identified
during CORE. [J Natl Cancer Inst 2004;96:1751–61]
Selective estrogen receptor modulators (SERMs) are a group
of nonsteroidal compounds that are chemically distinct from
estradiol and act as estrogen agonists in some tissues, such as
bone, and as estrogen antagonists in other tissues, such as breast,
through specific, high-affinity binding to the estrogen receptor
(ER). Because of their estrogen antagonist effects in the breast,
SERMs have been and continue to be studied for their effects on
breast cancer risk reduction. Tamoxifen, a triphenylethylene
SERM approved for the treatment of breast cancer, is the only
agent approved in the United States to reduce the incidence of
breast cancer in women at high risk for the disease (1).
Raloxifene (Evista) is a benzothiophene SERM that is chem-
ically distinct from tamoxifen. Raloxifene increases bone min-
eral density in postmenopausal women (2), reduces the risk of
vertebral fracture in postmenopausal women with osteoporosis
(3), and is approved in the United States and several other
countries for the prevention and treatment of postmenopausal
osteoporosis (4). Results of the Multiple Outcomes of Ralox-
ifene Evaluation (MORE) trial, in which the incidence of breast
cancer was a predefined secondary outcome provided the first
evidence of possible breast cancer risk reduction effects of
raloxifene therapy. In that trial, the incidence of invasive breast
cancer was reduced by 76% after 3 years (5) and by 72% after
4 years (6) among women treated with raloxifene compared with
women treated with placebo.
The Continuing Outcomes Relevant to Evista (CORE) trial was
designed to evaluate the efficacy of an additional 4 years of ralox-
ifene therapy in preventing invasive breast cancer in women who
participated in the MORE trial. Here we report the incidences of
invasive breast cancer during the 4 years of the CORE trial and
during the 8 years of the MORE and CORE trials.
METHODS
Study Design
CORE was a multicenter, double-blind, placebo-controlled
clinical trial. The primary objective of the CORE trial was to
investigate the effect of 4 additional years of raloxifene (at 60
mg/day) on the incidence of invasive breast cancer in postmeno-
pausal women with osteoporosis. The CORE trial was conducted
in the subset of the MORE cohort that agreed to participate in
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what was an extension of the MORE trial, with a change in the
primary endpoint from vertebral fracture incidence to invasive
breast cancer incidence effective January 1, 1999. A secondary
objective of the CORE trial was to examine the effect of ralox-
ifene (at 60 mg/day) on the incidence of invasive ER-positive
breast cancer. As specified in the CORE protocol, the observa-
tion period for the breast cancer–related objectives began on
January 1, 1999, during the fourth year of the MORE trial, and
continued through the additional 4 years of the CORE trial.
January 1, 1999, was chosen as the start date because data
collected before this date had been unblinded for the 3-year
MORE analysis. The CORE trial consisted of five visits. During
visit 1, the baseline visit, which took place 4.5–5 years after
random assignment to a MORE treatment group, the women
signed the informed consent document, received a clinical breast
exam, and had a mammogram unless one had already been
performed within the preceding 12 months. Visits 2, 3, 4, and 5
occurred during the double-blind treatment period and were
scheduled annually, approximately at the anniversary date of
their random assignment in the MORE trial. Mammograms were
scheduled for visit 3 and visit 5.
Subjects
Of the 180 investigative sites that participated in the MORE
trial, 130 sites in 24 countries agreed to participate in the CORE
trial. All MORE trial participants at these 130 sites who were
randomly assigned to receive raloxifene or placebo (N  6511)
were eligible for the CORE trial; the 4011 participants who
chose to enroll in the CORE trial will subsequently be referred
to as CORE enrollees (Fig. 1). Of the 2500 MORE trial partic-
ipants who chose not to enroll in the CORE trial, 1217 women
were still participating in the MORE trial as of January 1, 1999.
Those 1217 women contributed data for the CORE primary
breast cancer analysis from January 1, 1999, until their comple-
tion of the MORE trial. The remaining 1283 women had com-
pleted their participation in the MORE trial before January 1,
1999, and thus did not contribute data for any of the CORE trial
analyses. Fifteen CORE enrollees were diagnosed with breast
cancer before January 1, 1999, and were excluded from the
CORE breast cancer and sensitivity analyses but were included
in the safety analyses. Thus, the CORE primary breast cancer
analysis dataset included 1217 women who were still participat-
ing in the MORE trial as of the January 1, 1999, start date for
CORE, and 3996 CORE enrollees who had not been diagnosed
with breast cancer as of January 1, 1999, for a total of 5213
women (n  3510 on raloxifene and n  1703 on placebo).
Figure 1 shows the flow of participants from the MORE trial into
the CORE trial.
The eligibility criteria for enrollment in the MORE trial have
been described in detail (3,5). In brief, women were eligible for
the MORE trial if they were 80 years old or younger, had
osteoporosis, and were at least 2 years beyond menopause.
Osteoporosis was defined as a lumbar spine or femoral neck
bone mineral density T-score equal to or less than 2.5 according
to the densitometer manufacturer’s reference database or as the
presence of a vertebral fracture on a radiograph.
MORE participants were encouraged to continue in the
CORE trial even if they chose not to continue taking study
medication. In addition, according to the CORE protocol,
MORE participants were allowed to participate in the CORE
trial but were not allowed to take study medication if they had a
diagnosis of any malignancy considered to be estrogen depen-
dent (including malignancies of the breast or uterus); had a
history of venous thromboembolism; were undergoing treatment
with cholestyramine, prescribed raloxifene, tamoxifen, systemic
hormone therapy, or other reproductive-hormone products dur-
ing the CORE trial; had such severe postmenopausal symptoms
at visit 1 of CORE that estrogen therapy was required; or had a
safety concern during the MORE trial that necessitated unblind-
ing of their treatment assignment. Of the CORE enrollees, 811
women (20%) did not take study medication, either because they
met one of the criteria listed above (n  435) or because they
chose not to (n  376). For the 3200 women who resumed
taking study medication during the CORE trial, compliance was
assessed at each visit by dividing the difference between the
number of tablets dispensed and the number of tablets remaining
at each visit by the number of days on study. The participant was
considered to be compliant if this calculation produced a value
of 80% or greater as specified in the CORE protocol, on the basis
of the observation that more than 90% of both raloxifene and
placebo participants took at least 80% of the study medication
during the first 3 years of the MORE trial (5).
Women who participated in the CORE trial had been eligible
to enroll in the MORE trial because they had osteoporosis.
Therefore, during the CORE trial, participants were allowed to
take specific bone-active agents, including bisphosphonates, cal-
citonin, or fluoride, and all participants received daily supple-
ments of calcium (500 mg) and vitamin D (400–600 IU). At
Fig. 1. Flow of participants from the MORE trial into the CORE trial.
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each CORE visit, participants were asked specifically if they had
taken any hormones or SERMs.
The ethical review board for each investigative site approved
the CORE trial protocol. All women provided written informed
consent for participation in the CORE trial, in accordance with
principles outlined in the Declaration of Helsinki. Women who
participated in the MORE trial but chose not to participate in the
CORE trial had previously provided written informed consent
for their participation in MORE and contributed data for the
CORE analyses only for the time of their participation in
MORE.
Randomization and Treatment
CORE enrollees (n  4011) were not rerandomized; instead,
the randomization assignment from the MORE trial was carried
forward to the CORE trial. All CORE enrollees and investigators
remained blinded to treatment assignment from the beginning of
the MORE trial to the end of the CORE trial. Whereas the
MORE trial compared three treatment groups (raloxifene at 60
mg/day, raloxifene at 120 mg/day, and placebo), the CORE trial
compared only raloxifene at 60 mg/day (Evista; Eli Lilly and
Company, Indianapolis, IN) with placebo (tablets identical in
appearance to raloxifene; Eli Lilly and Company). The study
sponsor was Eli Lilly and Company, hereafter referred to as the
study sponsor. The CORE trial protocol was designed by the
study sponsor in consultation with the coordinating center at the
University of California, San Francisco. The statistical analysis
plan was written and executed by the study sponsor. We chose
raloxifene at 60 mg/day as the only active treatment in the
CORE trial because it is the dose that is approved for the
prevention and treatment of osteoporosis (4) and because the 60
mg/day and the 120 mg/day dosage groups in the MORE trial
had similar reductions in incidence of breast cancer (5,6). CORE
enrollees continued in their original randomized treatment
groups that were established in the MORE trial, i.e., those who
were randomly assigned to receive raloxifene at either 60 mg/day
or 120 mg/day in the MORE trial were assigned to receive
raloxifene at 60 mg/day in the CORE trial and those who were
randomly assigned to receive placebo in the MORE trial con-
tinued on placebo in the CORE trial. As a result, for the CORE
enrollees, approximately twice as many women were assigned to
the raloxifene group (n  2725) as to the placebo group (n 
1286).
Breast Cancer Ascertainment
At visit 1 of CORE, CORE enrollees provided information
about the risk factors that are included in the Gail breast cancer
risk assessment model; we used that information to calculate
their 5-year predicted risk of breast cancer as previously de-
scribed (7). These factors included current age, age at menarche,
age at first live birth, the number of breast biopsies, the presence
of atypical hyperplasia in a biopsy sample, the number of first-
degree relatives diagnosed with breast cancer, and race (white or
black). All CORE enrollees were required to have had a bilateral
mammogram within the year before they entered the CORE trial
or at entry into the CORE trial and at 2 and 4 years after entry
into the CORE trial. At each yearly visit, each woman was given
a clinical breast exam and asked if she had received a diagnosis
of breast cancer or had had a breast biopsy or breast surgery. We
obtained the medical records of any woman with a known or
suspected diagnosis of breast cancer. According to the study
protocol, study medications were stopped for these women, and
the medical records were sent for adjudication by an indepen-
dent review board that consisted of a radiologist (Valerie Jack-
son, MD, Indiana University, Indianapolis, IN), a surgical on-
cologist (S. Chace Lottich, MD, Center for Women’s Health,
Indianapolis, IN), and a medical oncologist (Kathy Miller, MD,
Indiana University, Indianapolis, IN), none of whom were em-
ployed by the study sponsor. The board reviewed all available
clinical data, including mammography films and reports, surgi-
cal records, and histopathology reports, and either rejected or
confirmed the diagnosis of breast cancer, including its invasive-
ness and ER status, without knowledge of the woman’s treat-
ment assignment.
Determination of Adverse Events
Adverse events for 8 years could be collected only for the
CORE enrollees (n  4011). At each annual visit, CORE en-
rollees were given a questionnaire that asked whether they had
experienced vaginal bleeding, endometrial hyperplasia, endome-
trial cancer, deep vein thrombosis, pulmonary embolism, or
retinal vein thrombosis. They were also questioned about any
other adverse events they had experienced and about their use of
medications. The determination of whether an adverse event met
the definition of a serious adverse event was made by the
investigator. A serious adverse event was defined as death, a
life-threatening experience, hospitalization, severe or permanent
disability, cancer, or any other clinically significant event. Ac-
cording to the CORE protocol, we recorded adverse events that
occurred among the CORE enrollees starting at visit 1 of CORE
and ending at visit 5. We report adverse events that occurred
among the CORE enrollees from visit 1 of CORE through visit
5, a total of 4 years, and from the time of randomization in
MORE to the end of CORE, a total of 8 years.
Statistical Analyses
By using a log-rank test as the primary statistical analysis and
by assuming an annual event rate for the placebo group of
0.334% based on MORE trial data and a relative risk of 0.34 for
the raloxifene group versus the placebo group, this study had a
91% power to detect a statistically significant difference in the
incidence of invasive breast cancer between the two groups for
a sample size of 4000 women. Data were analyzed by the study
sponsor according to a prospectively written statistical analysis
plan. Analyses were performed using the intent-to-treat ap-
proach, with all participants allocated to assigned treatment
regardless of whether she took study medication or other post-
baseline factors. Unless otherwise stated, all hypotheses were
tested at the 0.05 (two-sided) level of statistical significance.
Baseline characteristics were compared by using a Student’s t
test for continuous data and a chi-square test for categoric
parameters.
We used data from the primary breast cancer analysis dataset
(N 5213) for the primary CORE analysis, which compared the
incidence of invasive breast cancer in women assigned to ralox-
ifene (n  3510) with that in women assigned to placebo (n 
1703). The incidence of the first invasive breast cancer was
measured from January 1, 1999, and the statistical significance
of the difference in incidence between treatment groups was
assessed by using a log-rank test. We used a Cox proportional
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hazards model to assess treatment effect and to estimate hazard
ratios (HRs) with 95% confidence intervals (CIs). The propor-
tional hazards assumption was found to be valid for these data
when tested by addition of a time varying covariate to the model.
Time from January 1, 1999, to the end of participation in CORE
was calculated and used to compute the absolute incidence rate
per 1000 woman-years. We used the same survival analysis
approach to analyze the secondary endpoint, the incidence of
ER-positive invasive breast cancer, and to examine the sensitiv-
ity of the results to the specified population. As prespecified by
the statistical analysis plan, sensitivity analyses examined the
incidence of invasive breast cancer for the 3996 CORE enrollees
who did not have a breast cancer diagnosis as of the start of
CORE trial and for the 3200 CORE enrollees who took study
medication.
As part of the secondary analysis, we also examined the
incidence of invasive breast cancer in the 7705 women who were
enrolled in the MORE trial (hereafter referred to as MORE
participants) from their randomization in the MORE trial until
the end of their participation in the CORE trial or, for those who
chose not to enroll in CORE, until the end of their participation
in the MORE trial. Kaplan–Meier curves were generated for
each treatment group to show the cumulative incidence of inva-
sive breast cancer from MORE randomization to the end of
CORE, and a log-rank test was used to determine the statistical
significance of the difference in the survival curves for the two
treatment groups. Treatment effects were assessed by hazard
ratios and 95% CIs computed using the Cox proportional haz-
ards model, and the absolute incidence rate per 1000 woman-
years was computed based on the time from randomization in
MORE to end of participation in CORE.
Adverse events that either first occurred or worsened in
severity after enrollment in CORE were analyzed for the CORE
enrollees from CORE visit 1 to CORE visit 5 (4 years total) and
from randomization in MORE until the end of CORE (8 years
total). All adverse events were reported to the sponsor without
regard to possible causality or relationship to study drug. How-
ever, in this article, we report only the incidence of the specif-
ically solicited adverse events (i.e., vaginal bleeding, endome-
trial hyperplasia, endometrial cancer, deep vein thrombosis,
pulmonary embolism, and retinal vein thrombosis) as well as the
incidence of other adverse events with potential relevance to
raloxifene or to SERMs in general (i.e., flushing or hot flushes,
leg cramps, and peripheral edema). We used Fisher’s exact test
to determine the statistical significance of differences in the
incidence of adverse events reported for the two treatment
groups.
One planned interim analysis was performed after all CORE
enrollees had their mammogram and follow-up at 2 years after
entry into CORE (visit 3). Because the results of that analysis
revealed that the incidence of invasive breast cancer was not
statistically significantly different between the treatment groups
at the prespecified statistical significance level of .001, the data
monitoring board recommended that the study continue as
planned. For the final analysis, we tested the primary endpoint at
the .0495 level of statistical significance to maintain an overall
statistical significance level of .05 for the study.
RESULTS
Demographics, Baseline Characteristics, and Study
Accrual
The women who comprised the CORE breast cancer primary
analysis dataset and the CORE enrollees were subsets of the
MORE cohort and, as expected, were similar to each other and
to the MORE participants with respect to the MORE baseline
characteristics shown in Table 1. In addition, there was no
difference (P.05) in any of the baseline characteristics shown
in Table 1 between the placebo and raloxifene groups in any of
the three populations (data not shown). For the CORE enrollees,
there was no difference (P  .10) in mean weight change
between treatment groups from visit 1 through visit 5 of the
CORE trial or for the 8-year period of the MORE and CORE
trials combined (data not shown).
The beginning of the CORE trial did not coincide exactly
with the end of the MORE trial. The median time between the
end of participation in the MORE trial and enrollment in the
CORE trial was 10.6 months (range 2.6 to 62 months) for both
treatment groups. For approximately 95% of women assigned to
raloxifene and 94% of women assigned to placebo, the interval
between end of the MORE trial and their enrollment in the
CORE trial was less than 2 years. The median time from ran-
domization in MORE to end of participation in CORE was 7.9
years for each treatment group (range  4.6 to 8.5 years). For
the CORE enrollees, 17.7% of those assigned to placebo and









Mean age, y (SD) 66.5 (7.1) 66.2 (6.9) 65.8 (6.8)
Age 60 y, No. (%) 6283 (81.5) 4233 (81.2) 3213 (80.1)
Mean height, cm (SD) 159 (6.6) 159 (6.6) 159 (6.6)
Mean weight, kg (SD) 63.8 (10.6) 63.9 (10.2) 63.8 (10.0)
Mean BMI, kg/m2 (SD) 25.2 (4.0) 25.3 (3.9) 25.2 (3.9)
White, No. (%) 7372 (95.7) 4979 (95.5) 3857 (96.2)
Current smoker, No. (%) 1274 (16.7) 832 (16.2) 634 (16.0)
Consumes 4 alcoholic drinks/wk, No. (%) 1342 (17.4) 887 (17.0) 659 (16.4)
Mean time (y) since menopause, (SD) 18.7 (8.4) 18.4 (8.2) 17.9 (8.0)
Had family history of breast cancer, No. (%) 949 (12.6) 611 (12.0) 466 (11.9)
Had hysterectomy, No. (%) 1748 (22.7) 1113 (21.4) 818 (20.4)
Previous hormone therapy use, No. (%) 2235 (29.1) 1379 (26.5) 1024 (25.6)
*The CORE breast cancer primary analysis dataset and those enrolling in CORE are subsets of the MORE population and therefore cannot be statistically
compared with the MORE participants. SD  standard deviation; BMI  body mass index.
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18.4% of those assigned to raloxifene reported that they had
taken a hormone or a SERM during the interval between their
completion of the MORE trial and their enrollment in the CORE
trial (P  .63).
Women could continue in the CORE trial even if they expe-
rienced an adverse event while in the MORE trial and, as a result
of having had the adverse event, were no longer allowed to take
study medication or chose not to take study medication in the
CORE trial. Of the 4011 CORE enrollees, 80% (or 3200
women) resumed taking study medication; approximately 69%
of those women were considered to be compliant (i.e., they took
at least 80% of their study medication). There was no difference
between the placebo and raloxifene treatment groups in the
number of CORE enrollees who were compliant (P.05).
At CORE baseline (visit 1), 99.3% of the CORE enrollees
underwent mammography (Fig. 2). At visits 3 and 5 (which
occurred at 6 and 8 years, respectively, after randomization in
MORE), 98.1% and 98.3%, respectively, of those continuing in
the CORE trial had a mammogram performed. Overall, 85.8% of
the CORE enrollees (85.7% of those in the raloxifene group and
86.0% of those in the placebo group) completed the study. The
most common reason given for study discontinuation was per-
sonal decision, which was cited by 7.9% of those in the ralox-
ifene group and 6.4% those in the placebo group (P.05).
Among the CORE enrollees, there was no difference in the
mean ( standard deviation) 5-year predicted risk of breast
cancer, as determined by the Gail model (7), between those in
the raloxifene group and those in the placebo group (1.94% 
1.0% versus 1.94%  0.9%; P  .903). Among the CORE
enrollees, 52.9% of those in the placebo group versus 54.4% of
those in the raloxifene group (P  .37) were considered at high
risk for invasive breast cancer because their 5-year predicted risk
of breast cancer was 1.67% or greater.
Breast Cancer Incidence During the CORE Trial
During the 4 years of the CORE trial, 61 cases of breast
cancer (30 in the placebo group and 31 in the raloxifene group)
were reported and confirmed by adjudication. Fourteen of these
cases, eight in the placebo group and six in the raloxifene group,
were previously reported by Cauley et al. (6). Of the 61 breast
cancer cases, 52 cases (28 in the placebo group and 24 in the
raloxifene group) were classified as invasive breast cancer (Ta-
ble 2). Women in the raloxifene group had a 59% reduction in
the incidence of invasive breast cancer compared with women in
the placebo group (2.1 versus 5.2 cases per 1000 woman-years;
HR  0.41, 95% CI  0.24 to 0.71). The ER status was
determined for 46 of the 52 cases of invasive breast cancer; 36
cases (78%) were ER positive. Women in the raloxifene group
had a 66% reduction in the incidence of invasive ER-positive
breast cancers compared with women in the placebo group (1.3
versus 3.9 cases per 1000 woman-years; HR  0.34, 95% CI 
0.18 to 0.66) (Table 2). By contrast, the incidence of invasive
ER-negative breast cancer in women who received raloxifene
was not statistically significantly different from that in women
who received placebo (HR  1.13, 95% CI  0.29 to 4.35; P 
.86) (Table 2). We were unable to classify the ER status for six
cases (two cases in the raloxifene group and four cases in the
placebo group) because of insufficient data. Nine noninvasive
breast cancers were reported, seven in the raloxifene group
and two in the placebo group (HR  1.78, 95% CI  0.37 to
8.61; P  .47) (Table 2). The overall incidence of breast
cancer, regardless of invasiveness, was reduced by 50% in the
raloxifene group compared with the placebo group (2.7 versus
5.5 cases per 1000 woman-years; HR  0.50, 95% CI  0.30
to 0.82) (Table 2).
Breast Cancer Incidence for 8 Years From Randomization
in MORE to the End of CORE
For the 7705 MORE participants, the total number of re-
ported breast cancers confirmed by adjudication from random-
ization in MORE to the end of their participation in either
MORE or CORE was 121 (56 cancers in the raloxifene group
and 65 cancers in the placebo group). During these 8 years, 40
invasive breast cancers were reported in the raloxifene group
(1.4 cases per 1000 woman-years) and 58 invasive breast can-
cers were reported in the placebo group (4.2 cases per 1000
woman-years); thus, the raloxifene group had a 66% reduction in
the incidence of invasive breast cancer compared with the pla-
cebo group (HR  0.34, 95% CI  0.22 to 0.50) (Fig. 3). ER
status was determined for 88 cases, and 75% of these were ER
positive. During these 8 years, the raloxifene group had a 76%
reduction in the incidence of invasive ER-positive breast cancer
compared with the placebo group (0.8 versus 3.2 cases per 1000
woman-years; HR  0.24; 95% CI  0.15 to 0.40) (Fig. 4).
There was no difference in the incidence rates of invasive
ER-negative breast cancer between the raloxifene group and the
placebo group (0.53 versus 0.51 per 1000 woman-years; HR 
1.06; 95% CI  0.43 to 2.59; P  .90) (Fig. 4). Insufficient data
Fig. 2. Follow-up of CORE trial enrollees. Visit 1 was scheduled at time of
enrollment in the CORE trial and generally occurred 4.5–5 years after random-
ization in the MORE trial. Visits 2, 3, 4, and 5 occurred approximately 5, 6, 7,
and 8 years, respectively, after randomization in the MORE trial. The category
“other” under “Reasons for withdrawal” included participant having moved,
protocol entry criteria not having been met, and protocol variance.
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were available to classify the ER status of 10 cases, three of
which occurred in the raloxifene group. There was no statisti-
cally significant difference in the incidence of noninvasive
breast cancers reported in the two treatment groups (16 cases for
the raloxifene group versus 7 cases for the placebo group; HR 
1.12, 95% CI 0.46 to 2.73; P .80). During the 8 years of the
MORE and CORE trials, the overall incidence of breast cancer,
regardless of invasiveness, was reduced by 58% in the raloxifene
group compared with the placebo group (HR  0.42, 95% CI 
0.29 to 0.60; P.001).
Breast Cancer Sensitivity Analyses
Fifteen of the CORE enrollees were diagnosed with breast
cancer before January 1, 1999, the start date for CORE data
collection, and therefore were not included in the sensitivity
analysis. Among the 3996 CORE enrollees who did not have a
breast cancer diagnosis at the start of CORE, those in the
raloxifene group had a 58% reduction in the incidence of inva-
sive breast cancer compared with those in the placebo group (1.9
versus 4.6 cases per 1000 woman-years; HR  0.42, 95% CI 
0.23 to 0.75). Among the 3200 CORE enrollees who resumed
taking study medication upon enrollment in the CORE trial,
those in the raloxifene group had a 64% reduction in the inci-
dence of invasive breast cancer compared with those in the
placebo group (HR  0.36; 95% CI  0.17 to 0.74).
Adverse Events
During the 4 years of the CORE trial, 80% of the CORE
enrollees reported an adverse event (79.9% of women in the
Fig. 3. Cumulative incidence of adjudicated invasive breast cancers per 1000
women over the 8 years from randomization in the MORE trial to the end of the
CORE trial for the 7705 MORE participants. Statistical significance of the
difference between treatment groups was assessed by a two-sided log-rank test.
Fig. 4. Annual incidence rate per 1000 woman-years of follow-up for adjudicated
invasive breast cancers over the 8 years from the time of randomization in the
MORE trial to the end of the CORE trial for the 7705 MORE participants. The
numbers of ER-positive invasive breast cancers in the placebo and raloxifene groups
were 44 and 22, respectively; the numbers of ER-negative invasive breast cancers in
the placebo and raloxifene groups were 7 and 15, respectively. Hazard ratios and
95% CIs for the raloxifene group relative to placebo are shown for ER-positive and
ER-negative invasive breast cancers. Statistical significance of the difference be-
tween treatment groups was assessed by two-sided log-rank tests.








% (No.) Rate‡ % (No.) Rate‡ HR§ (95% CI) P
Invasive breast cancer 1.6 (28) 5.2 0.7 (24) 2.1 0.41 (0.24 to 0.71) .001
ER-positive 1.2 (21) 3.9 0.4 (15) 1.3 0.34 (0.18 to 0.66) .001
ER-negative 0.18 (3) 0.55 0.20 (7) 0.61 1.13 (0.29 to 4.35) .86
ER status unknown 0.23 (4) 0.74 0.06 (2) 0.17 0.24 (0.04 to 1.30) .071
Noninvasive breast cancer 0.1 (2) 0.37 0.2 (7) 0.61 1.78 (0.37 to 8.61) .47
All breast cancer¶ 1.8 (30) 5.5 0.9 (31) 2.7 0.50 (0.30 to 0.82) .005
*CORE  Continuing Outcomes Relevant to Evista; CI  confidence interval; ER  estrogen.
†Dose of 60 mg of raloxifene per day.
‡Number of cases per 1000 woman-years.
§Based on Cox proportional hazards model.
Assessed by the log-rank test (two-sided).
¶Includes invasive and noninvasive breast cancer.
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raloxifene group versus 80.0% of women in the placebo group,
P  .97; Table 3). There were no statistically significant differ-
ences between the raloxifene group and the placebo group in
the percentage of women who stopped taking study medica-
tion because of an adverse event (1.9% versus 2.4%; P 
.35). There were no statistically significant differences be-
tween treatment groups in the percentage of women reporting
a serious adverse event (24.7% for placebo versus 22.8% for
raloxifene; P  .22) or in the number of deaths reported (29
deaths in the placebo group versus 47 deaths in the raloxifene
group; P  .27) (Table 3). No deaths due to breast cancer
were reported during the CORE trial. During the 8 years of
the MORE and CORE trials, one death due to breast cancer
was reported during the MORE trial in a woman assigned to
the raloxifene group (6).
The reported incidences of vaginal bleeding, endometrial
hyperplasia, and endometrial cancer were not statistically sig-
nificantly different for the two treatment groups during the 4
years of the CORE trial or during the 8 years of the MORE and
CORE trials (P.2 for each event; Table 4). During the 4 years
of the CORE trial, the incidences of hot flushes, leg cramps, and
peripheral edema, adverse events that are known to be associated
with raloxifene therapy, were not statistically significantly dif-
ferent between treatment groups (P.5 for each event; Table 4).
For the 8 years from randomization in the MORE trial to the end
of the CORE trial, hot flushes and leg cramps, but not peripheral
edema, were reported more often by women in the raloxifene
group than by women in the placebo group (P.001, P  .008,
and P  .24, respectively; Table 4). During the 4 years of the
CORE trial and during the 8 years of the MORE and CORE
trials, there were no statistically significant differences in the
incidence of ovarian cancer, breast symptoms (e.g., breast pain),
pelvic prolapse, cataracts, stroke, or myocardial infarction be-
tween the raloxifene and placebo groups (P.1 for each event;
data not shown).
Thromboembolic disease is a serious adverse event asso-
ciated with raloxifene therapy (6). Although women in the
raloxifene group had a higher incidence of thromboembolic
disease, including deep vein thrombosis, pulmonary embo-
lism, and retinal vein thrombosis, than women in the placebo
group, those differences were not statistically significant,
either during the 4 years of the CORE trial (P  .15) or
during the 8 years of the MORE and CORE trials (P  .094)
(Table 4). During the CORE trial, the relative risk of throm-
boembolism in the raloxifene group (2.9 events per 1000
woman-years) compared with those in the placebo group (1.3
events per 1000 woman-years) was 2.17 (95% CI  0.83 to
5.70) for the CORE enrollees and 3.11 (95% CI  0.92 to
10.44) for the 3200 CORE enrollees who resumed taking
study medication during the CORE trial. During the 8 years of
the MORE and CORE trials, the incidence rate for venous
thromboembolic events was 2.2 and 1.3 events per 1000
woman-years for the raloxifene and placebo groups, respec-
tively. During the CORE trial, no cases of pulmonary embo-
Table 3. Overview of adverse events reported during the CORE trial*
Adverse event†






Deaths 2.3 (29) 1.7 (47) .27
Serious adverse events 24.7 (317) 22.8 (622) .22
All adverse events¶ 80.0 (1029) 79.9 (2178) .97
Discontinuations from
the CORE trial due
to an adverse event
2.4 (31) 1.9 (53) .35
*Visit 1 in the CORE trial occurred approximately 4.5–5 years after women
were randomly assigned to treatment groups in the MORE trial. CORE 
Continuing Outcomes Relevant to Evista; MORE  Multiple Outcomes of
Raloxifene Evaluation.
†Women may be counted in more than one category.
‡Dose of 60 mg of raloxifene per day.
§Based on Fisher’s exact test (two-sided).
Defined as an adverse event associated with death, a life-threatening expe-
rience, hospitalization, severe or permanent disability, cancer, or any other
clinically significant event.
¶Adverse events that first occurred or worsened in severity after enrollment in
CORE.
Table 4. Rates of adverse events among the CORE enrollees*
Adverse event
CORE enrollees, % (No.)








(N  2725) P‡
Vaginal bleeding 0.20 (2) 0.19 (4) .99 1.36 (14) 1.25 (27) .87
Endometrial hyperplasia 0.20 (2) 0.05 (1) .24 0.29 (3) 0.37 (8) .99
Endometrial cancer 0.30 (3) 0.19 (4) .69 0.39 (4) 0.32 (7) .75
Thromboembolic disease 0.39 (5) 0.84 (23) .15 1.01 (13) 1.72 (47) .094
Deep vein thrombosis 0.39 (5) 0.62 (17) .49 0.78 (10) 1.14 (31) .32
Pulmonary embolism 0.00 (0) 0.33 (9) .066 0.16 (2) 0.62 (17) .048
Retinal vein thrombosis 0.00 (0) 0.07 (2) .99 0.16 (2) 0.22 (6) .99
Flushing (hot flushes) 0.86 (11) 1.10 (30) .61 6.92 (89) 12.55 (342) .001
Leg cramps 3.11 (40) 3.56 (97) .52 11.82 (152) 14.94 (407) .008
Peripheral edema 2.41 (31) 2.50 (68) .91 9.33 (120) 10.57 (288) .24
*CORE  Continuing Outcomes of Relevant to Evista; MORE  Multiple Outcomes of Raloxifene Evaluation.
†Dose of 60 mg of raloxifene per day during the CORE trial.
‡Based on two-sided Fisher’s exact test.
§Doses of 60 mg or 120 mg of raloxifene per day during the MORE trial and 60 mg of raloxifene per day during the CORE trial.
Includes only women who had an intact uterus at baseline of the MORE trial. For 4 years beginning at visit 1 of CORE, n  1008 and n  2138 for the placebo
and raloxifene groups, respectively. For 8 years beginning at randomization in MORE, n  1026 and n  2167 for the placebo and raloxifene groups, respectively.
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lism were reported in the placebo group, compared with nine
cases reported in the raloxifene group (P  .066). During the
8 years from randomization in MORE until the end of the
CORE trial, two women assigned to placebo (0.16%) and 17
women assigned to raloxifene (0.62%) developed a pulmo-
nary embolism (P  .048; Table 4). One death due to pul-
monary embolism was reported in the raloxifene group during
the 4 years of the CORE trial.
DISCUSSION
During the CORE trial, raloxifene statistically significantly
reduced the 4-year incidence of invasive breast cancer and of
invasive ER-positive breast cancer by 59% and 66%, respec-
tively. The reduction in the incidence of invasive breast cancer
observed among women in the raloxifene group during the 4
years of the MORE trial was also observed for the additional 4
years that they participated in the CORE trial. Thus, the reduc-
tion in invasive breast cancer incidence continued throughout
the 8 years for women assigned to raloxifene, and the magnitude
of the risk reduction during the second 4 years of raloxifene
therapy was similar to that observed during the first 4 years of
therapy (6). It is possible that some of the risk reduction ob-
served during the second 4 years (i.e., during the CORE trial)
could be a carryover effect from the first 4 years of therapy in the
MORE trial. Although the CORE trial was not designed to
examine this question, the consistent risk reduction over the 8
years as shown in Fig. 3 implies that at least some of the risk
reduction comes from continuing therapy beyond 4 years. As
previously reported for the MORE trial (5,6), and as we now also
report for the CORE trial, the incidence of ER-negative invasive
breast cancer in women who received raloxifene was similar to
that in women who received placebo. The lack of an apparent
effect of raloxifene on ER-negative invasive breast cancers
provides additional support for the hypothesis that SERMs in-
hibit estrogen-induced proliferation by binding to ERs in the
breast (8,9). We found that raloxifene had no apparent effect on
noninvasive breast cancer during the CORE trial, consistent with
previously reported results from the MORE trial (5,6). Thus, the
reduction in incidence of breast cancer observed with raloxifene
appears to be limited to ER-positive invasive breast cancer.
Tamoxifen has also been reported to reduce the risk of
invasive breast cancer among women who are at high risk for
breast cancer (10). The breast cancer prevention effects of ta-
moxifen have been studied in four clinical trials (11–14). Com-
bined results from these four trials showed that, compared with
placebo, tamoxifen at 20 mg/day reduced the incidence of inva-
sive breast cancer by approximately 36% and the incidence of
ER-positive invasive breast cancer by 48% in pre- and post-
menopausal women at high risk of breast cancer (10). In the
largest of these four prevention trials, the Breast Cancer Preven-
tion Trial (P-1) conducted by the National Surgical Adjuvant
Breast and Bowel Project (14), tamoxifen reduced the incidence
of invasive breast cancer and of invasive ER-positive breast
cancer by 49% and 69%, respectively, compared with placebo,
after a median follow-up of 54.6 months. By contrast, tamoxifen
did not reduce the risk of ER-negative breast cancer (10,13,14).
The P-1 trial also showed that tamoxifen reduced the risk of
noninvasive breast cancer by 50% (14), a result that differs from
our finding that raloxifene had no effect on noninvasive breast
cancer incidence. There are several possible explanations for this
apparent difference between the effects of tamoxifen and ralox-
ifene on the incidence of noninvasive breast cancer. These
include the lack of a sufficient number of cases of noninvasive
breast cancer reported in the MORE and CORE trials to detect
a treatment difference, differences in the populations studied
(pre- and postmenopausal women in the P-1 trial versus post-
menopausal women with osteoporosis in the MORE and CORE
trials), and differences in the biologic activities of raloxifene and
tamoxifen. Results of the ongoing Study of Tamoxifen and
Raloxifene (STAR) trial, which directly compares the effects of
raloxifene and tamoxifen in postmenopausal women at high risk
for breast cancer, may clarify the basis for this difference
(15,16).
Tamoxifen is approved in the United States for the reduction
in incidence of breast cancer in women at high risk (defined as
being at least 35 years of age with a 5-year predicted risk of
breast cancer of 1.67% or greater, as calculated by the Gail
model) for the disease (1). The maximum duration recom-
mended for this use of tamoxifen is 5 years, presumably based
on the limited clinical trial experience with more than 5 years of
use in the prevention setting and on breast cancer treatment data
suggesting that continuation of tamoxifen therapy beyond 5
years in the adjuvant setting may not provide additional benefit
(17). The data from the CORE trial and the 8-year data from the
MORE and CORE trials suggest that the reduction in incidence
of invasive breast cancer in women receiving raloxifene may
continue beyond 5 years.
Women with osteoporosis or low bone mineral density are
considered to be at a lower risk for breast cancer than women
with high bone mineral density, possibly because bone mineral
density directly reflects a woman’s lifetime exposure to estrogen
(18–20). Because the CORE enrollees had osteoporosis, one
might have expected their breast cancer risk to be low. A 5-year
predicted risk for invasive breast cancer of 1.67% or greater, as
estimated by the Gail model (7), is commonly used to classify
women as being at high risk for invasive breast cancer. At
CORE baseline, the mean 5-year predicted risk for invasive
breast cancer for the CORE enrollees was 1.94% for both the
raloxifene and placebo groups; therefore, both groups would be
considered to be at high risk for breast cancer. The breast cancer
incidence rate for the placebo group in the CORE trial was 5.4
cases per 1000 woman-years. This incidence rate is slightly
higher than the incidence rates of 4.4 and 4.5 cases per 1000
woman-years for women who are 65–74 years of age and those
75 years or older, respectively, reported by the National Cancer
Institute’s Surveillance, Epidemiology, and End Results Pro-
gram (21). These data suggest that the CORE participants were
not at a lower risk for breast cancer than the general population,
despite having osteoporosis, and suggest that postmenopausal
women with low bone mineral density or osteoporosis should
not be assumed to be at a low risk of breast cancer.
Raloxifene was generally well tolerated during the 4 years of
the CORE trial and during the 8 years from randomization in the
MORE trial to the end of the CORE trial. During the CORE trial,
women who received raloxifene reported no increase in breast
symptoms, including breast pain, consistent with the observa-
tions from the MORE trial (6). During the 8 years of the MORE
and CORE trials, raloxifene increased the risk for hot flushes and
leg cramps compared with placebo; these increased risks were
observed during the MORE trial (6) but not during the additional
4 years of therapy in CORE, suggesting that hot flushes and leg
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cramps may be early events which do not persist with continued
therapy. Alternatively, it is possible that we did not observe an
increased risk of these adverse events during the CORE trial
because of selection bias, i.e., women who experienced hot
flushes and leg cramps during the MORE trial may have chosen
not to continue in the CORE trial. During the CORE trial,
raloxifene did not increase the incidence of vaginal bleeding,
endometrial hyperplasia, or endometrial cancer compared with
placebo, consistent with previous results from the MORE trial
(5,6) and other raloxifene trials (22). By contrast, tamoxifen
therapy has been associated with increased incidence of endo-
metrial cancer (10,13,14). The observations that raloxifene does
not increase the incidence of endometrial cancer and that tamox-
ifen is associated with an increased incidence of endometrial
cancer may be clinically important.
Another clinically important question is whether a decrease in
the incidence of invasive breast cancer translates into a survival
benefit. During the CORE trial, there was no difference between
the raloxifene and the placebo groups in the number of deaths
from any cause, and no deaths due to breast cancer were re-
ported. Because survival was not an endpoint of the CORE trial,
these data should not be used to draw any conclusions about the
possible survival benefits associated with raloxifene therapy.
Thromboembolic disease is a serious adverse event associ-
ated with raloxifene therapy (6), and raloxifene is contraindi-
cated in women with active or past history of venous thrombo-
embolic events, including deep vein thrombosis, pulmonary
embolism, and retinal vein thrombosis (4). The twofold increase
in venous thromboembolic events observed for the raloxifene
group in the CORE trial was similar to that reported for the
MORE trial (23). The most life-threatening complication of
thromboembolic disease is pulmonary embolism, which, al-
though an uncommon event, occurred more frequently in the
raloxifene group than the placebo group. During the CORE trial,
nine cases of pulmonary embolism were reported, all in the
raloxifene group. The increased risk for venous thromboembo-
lism must be considered when raloxifene is used.
The CORE trial, when combined with the MORE trial, pro-
vides clinical trial data for approximately 8 years of exposure to
raloxifene, the longest duration of clinical trial exposure for this
drug. This long-term study of raloxifene effects was possible
because the randomization assignment from the MORE trial was
carried forward into the CORE trial and because CORE trial
participants remained blinded to therapy assignment. Neverthe-
less, the CORE trial has several limitations. First, because both
the MORE investigators and the MORE trial participants, in
consultation with the investigator, could choose whether or not
to continue in the CORE trial, selection bias could have been
introduced. For example, less healthy and/or more symptomatic
women may have chosen not to continue in the CORE trial.
Second, because the beginning of the CORE trial did not coin-
cide with the end of the MORE trial, there was a gap between the
two trials, during which time women could have taken pre-
scribed raloxifene, hormone therapy, or no therapy. Use or lack
of use of raloxifene or hormone therapy during the gap could
have confounded interpretation of the results for both the ralox-
ifene and placebo groups. Third, approximately 20% of the
women who enrolled in the CORE trial never resumed taking the
study medication, which could have reduced the effects ob-
served for breast cancer incidence and venous thromboembolism
in the raloxifene group. However, the sensitivity analysis of the
3200 women who resumed taking study medication showed a
similar reduction in invasive breast cancer risk and a similar
increase in relative risk of thromboembolism. Fourth, because
all CORE trial participants were postmenopausal women with
osteoporosis (defined by low femoral neck or lumbar spine bone
mineral density or a history of fracture), our results cannot be
extrapolated to other populations, including premenopausal
women, for whom raloxifene is not indicated. In addition, most
of the women in our study were white, which may limit extrap-
olation of our results to other racial groups.
In summary, these data demonstrate that the incidence of
ER-positive invasive breast cancer continues to be reduced
through 8 years of raloxifene treatment in postmenopausal
women with osteoporosis. No increase in the incidence of ER-
negative breast cancer was observed. During 8 years of ralox-
ifene therapy, there was no increase in endometrial cancer and,
except for those that have been previously reported, no other
safety concerns were noted. The effect of raloxifene on breast
cancer incidence is currently being evaluated in postmenopausal
women at high risk for heart disease in the Raloxifene Use for
The Heart (RUTH) trial (24,25) and in postmenopausal women
at high risk for breast cancer in the STAR trial (15,16).
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